Hemant Surgical Industries Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: April 24, 2025, 9:35 pm

Market Cap	111 Cr.
Current Price	106
High / Low	225/88.2
Stock P/E	12.2
Book Value	55.6
Dividend Yield	0.00 %
ROCE	29.8 %
ROE	25.0 %
Face Value	10.0
PEG Ratio	-0.35

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Hemant Surgical Industries Ltd

Competitors of Hemant Surgical Industries Ltd

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
Hemant Surgical Industries Ltd	111 Cr.	106	225/88.2	12.2	55.6	0.00 %	29.8 %	25.0 %	10.0
Industry Average	111.00 Cr	106.00		12.20	55.60	0.00%	29.80%	25.00%	10.00

All Competitor Stocks of Hemant Surgical Industries Ltd

Quarterly Result

Metric	Sep 2022	Mar 2023	Sep 2023	Mar 2024	Sep 2024
Sales	51	58	48	58	49
Expenses	47	52	44	51	45
Operating Profit	4	6	3	7	4
OPM %	8%	11%	7%	13%	7%
Other Income	1	1	3	2	2
Interest	1	1	1	0	1
Depreciation	0	0	1	1	1
Profit before tax	4	6	5	8	4
Tax %	36%	18%	17%	27%	29%
Net Profit	2	5	4	6	3
EPS in Rs	48.12	6.93	3.75	5.63	3.05

Last Updated: February 28, 2025, 7:26 pm

Below is a detailed analysis of the quarterly data for Hemant Surgical Industries Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:

For Sales, as of Sep 2024, the value is 49.00 Cr.. The value appears to be declining and may need further review. It has decreased from 58.00 Cr. (Mar 2024) to 49.00 Cr., marking a decrease of 9.00 Cr..
For Expenses, as of Sep 2024, the value is 45.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 51.00 Cr. (Mar 2024) to 45.00 Cr., marking a decrease of 6.00 Cr..
For Operating Profit, as of Sep 2024, the value is 4.00 Cr.. The value appears to be declining and may need further review. It has decreased from 7.00 Cr. (Mar 2024) to 4.00 Cr., marking a decrease of 3.00 Cr..
For OPM %, as of Sep 2024, the value is 7.00%. The value appears to be declining and may need further review. It has decreased from 13.00% (Mar 2024) to 7.00%, marking a decrease of 6.00%.
For Other Income, as of Sep 2024, the value is 2.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 2.00 Cr..
For Interest, as of Sep 2024, the value is 1.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.00 Cr. (Mar 2024) to 1.00 Cr., marking an increase of 1.00 Cr..
For Depreciation, as of Sep 2024, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 1.00 Cr..
For Profit before tax, as of Sep 2024, the value is 4.00 Cr.. The value appears to be declining and may need further review. It has decreased from 8.00 Cr. (Mar 2024) to 4.00 Cr., marking a decrease of 4.00 Cr..
For Tax %, as of Sep 2024, the value is 29.00%. The value appears to be increasing, which may not be favorable. It has increased from 27.00% (Mar 2024) to 29.00%, marking an increase of 2.00%.
For Net Profit, as of Sep 2024, the value is 3.00 Cr.. The value appears to be declining and may need further review. It has decreased from 6.00 Cr. (Mar 2024) to 3.00 Cr., marking a decrease of 3.00 Cr..
For EPS in Rs, as of Sep 2024, the value is 3.05. The value appears to be declining and may need further review. It has decreased from 5.63 (Mar 2024) to 3.05, marking a decrease of 2.58.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: March 6, 2025, 4:01 pm

Metric	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	TTM
Sales	51	56	56	60	101	109	106	107
Expenses	48	53	53	57	95	98	95	96
Operating Profit	2	3	3	3	6	11	10	11
OPM %	5%	5%	5%	5%	6%	10%	10%	10%
Other Income	0	0	0	1	2	2	4	4
Interest	1	1	2	2	2	2	1	1
Depreciation	0	1	0	1	1	1	1	1
Profit before tax	1	1	1	1	6	10	13	13
Tax %	10%	8%	41%	9%	25%	24%	23%
Net Profit	1	1	0	1	5	8	10	9
EPS in Rs	50.76	61.02	27.00	73.43	248.92	9.95	9.39	8.68
Dividend Payout %	0%	0%	0%	0%	0%	0%	0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2018-2019	2019-2020	2021-2022	2022-2023	2023-2024
YoY Net Profit Growth (%)	0.00%	-100.00%	400.00%	60.00%	25.00%
Change in YoY Net Profit Growth (%)	0.00%	-100.00%	500.00%	-340.00%	-35.00%

Hemant Surgical Industries Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 5 years from 2018-2019 to 2023-2024.

Growth

Compounded Sales Growth
10 Years:	%
5 Years:	14%
3 Years:	21%
TTM:	1%

Compounded Profit Growth
10 Years:	%
5 Years:	54%
3 Years:	93%
TTM:	-2%

Stock Price CAGR
10 Years:	%
5 Years:	%
3 Years:	%
1 Year:	-25%

Return on Equity
10 Years:	%
5 Years:	28%
3 Years:	32%
Last Year:	25%

Last Updated: Unknown

Balance Sheet

Last Updated: November 14, 2024, 11:33 pm

Month	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Sep 2024
Equity Capital	2	2	2	2	2	8	10	10
Reserves	5	6	5	8	11	16	44	48
Borrowings	9	11	14	14	10	7	7	14
Other Liabilities	12	14	23	15	32	34	35	43
Total Liabilities	28	33	44	40	54	65	97	116
Fixed Assets	7	8	10	11	12	13	18	33
CWIP	0	0	0	0	0	0	0	0
Investments	0	0	1	0	1	0	5	0
Other Assets	21	25	33	29	42	51	74	83
Total Assets	28	33	44	40	54	65	97	116

Below is a detailed analysis of the balance sheet data for Hemant Surgical Industries Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:

For Equity Capital, as of Sep 2024, the value is ₹10.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 10.00 Cr..
For Reserves, as of Sep 2024, the value is ₹48.00 Cr.. The value appears strong and on an upward trend. It has increased from 44.00 Cr. (Mar 2024) to ₹48.00 Cr., marking an increase of 4.00 Cr..
For Borrowings, as of Sep 2024, the value is ₹14.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 7.00 Cr. (Mar 2024) to ₹14.00 Cr., marking an increase of 7.00 Cr..
For Other Liabilities, as of Sep 2024, the value is ₹43.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 35.00 Cr. (Mar 2024) to ₹43.00 Cr., marking an increase of 8.00 Cr..
For Total Liabilities, as of Sep 2024, the value is ₹116.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 97.00 Cr. (Mar 2024) to ₹116.00 Cr., marking an increase of 19.00 Cr..
For Fixed Assets, as of Sep 2024, the value is ₹33.00 Cr.. The value appears strong and on an upward trend. It has increased from 18.00 Cr. (Mar 2024) to ₹33.00 Cr., marking an increase of 15.00 Cr..
For CWIP, as of Sep 2024, the value is ₹0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
For Investments, as of Sep 2024, the value is ₹0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 5.00 Cr. (Mar 2024) to ₹0.00 Cr., marking a decrease of 5.00 Cr..
For Other Assets, as of Sep 2024, the value is ₹83.00 Cr.. The value appears strong and on an upward trend. It has increased from 74.00 Cr. (Mar 2024) to ₹83.00 Cr., marking an increase of 9.00 Cr..
For Total Assets, as of Sep 2024, the value is ₹116.00 Cr.. The value appears strong and on an upward trend. It has increased from 97.00 Cr. (Mar 2024) to ₹116.00 Cr., marking an increase of 19.00 Cr..

Notably, the Reserves (48.00 Cr.) exceed the Borrowings (14.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

Month	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Cash from Operating Activity +	-0	-0	2	-4	12	6	-8
Cash from Investing Activity +	-0	-0	-2	-2	-0	-3	-9
Cash from Financing Activity +	-0	-0	2	5	-8	-1	21
Net Cash Flow	-0	-0	2	-2	4	3	5

Free Cash Flow

Month	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Free Cash Flow	-7.00	-8.00	-11.00	-11.00	-4.00	4.00	3.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Debtor Days	35	36	35	26	56	58	75
Inventory Days	64	73	125	113	57	67	99
Days Payable	102	97	143	89	92	110	116
Cash Conversion Cycle	-3	12	17	51	21	15	58
Working Capital Days	12	23	14	66	2	16	74
ROCE %		15%	12%	14%	32%	45%	30%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Sep 2023	Mar 2024	Sep 2024
Promoters	73.56%	73.56%	73.56%
FIIs	0.03%	0.00%	0.00%
DIIs	4.26%	1.97%	1.13%
Public	22.14%	24.47%	25.31%
No. of Shareholders	722	1,229	1,248

Shareholding Pattern Chart

No. of Shareholders

This stock is not held by any mutual fund

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20
FaceValue	10.00	10.00	10.00	10.00	100.00
Basic EPS (Rs.)	9.85	10.28	8.96	2.22	32.90
Diluted EPS (Rs.)	9.85	10.28	8.96	2.22	32.90
Cash EPS (Rs.)	10.37	11.07	26.81	8.90	73.82
Book Value[Excl.RevalReserv]/Share (Rs.)	52.55	30.73	65.74	42.67	400.80
Book Value[Incl.RevalReserv]/Share (Rs.)	52.55	30.73	65.74	42.67	400.80
Revenue From Operations / Share (Rs.)	101.16	142.12	517.85	298.82	2805.11
PBDIT / Share (Rs.)	14.16	16.69	42.50	19.81	150.54
PBIT / Share (Rs.)	13.17	15.59	38.76	16.64	119.62
PBT / Share (Rs.)	12.24	13.10	30.56	7.60	47.90
Net Profit / Share (Rs.)	9.39	9.96	23.07	5.73	42.90
PBDIT Margin (%)	13.99	11.74	8.20	6.62	5.36
PBIT Margin (%)	13.02	10.96	7.48	5.56	4.26
PBT Margin (%)	12.10	9.21	5.90	2.54	1.70
Net Profit Margin (%)	9.27	7.00	4.45	1.91	1.52
Return on Networth / Equity (%)	17.86	32.42	35.09	13.42	10.70
Return on Capital Employeed (%)	23.37	44.37	44.51	16.47	14.29
Return On Assets (%)	10.14	11.78	8.48	2.66	2.07
Long Term Debt / Equity (X)	0.06	0.12	0.31	1.21	1.09
Total Debt / Equity (X)	0.12	0.30	0.74	1.69	1.76
Asset Turnover Ratio (%)	1.31	1.83	2.13	1.42	1.50
Current Ratio (X)	1.83	1.23	1.02	1.13	1.05
Quick Ratio (X)	1.28	0.84	0.67	0.47	0.45
Inventory Turnover Ratio (X)	4.47	5.93	5.89	3.32	3.88
Interest Coverage Ratio (X)	15.21	6.70	5.19	2.19	2.10
Interest Coverage Ratio (Post Tax) (X)	11.09	5.00	3.81	1.63	1.60
Enterprise Value (Cr.)	132.59	0.00	0.00	0.00	0.00
EV / Net Operating Revenue (X)	1.26	0.00	0.00	0.00	0.00
EV / EBITDA (X)	8.97	0.00	0.00	0.00	0.00
MarketCap / Net Operating Revenue (X)	1.32	0.00	0.00	0.00	0.00
Price / BV (X)	2.53	0.00	0.00	0.00	0.00
Price / Net Operating Revenue (X)	1.32	0.00	0.00	0.00	0.00
EarningsYield	0.07	0.00	0.00	0.00	0.00

After reviewing the key financial ratios for Hemant Surgical Industries Ltd, here is a detailed analysis based on the latest available data and recent trends:

For FaceValue, as of Mar 24, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 10.00.
For Basic EPS (Rs.), as of Mar 24, the value is 9.85. This value is within the healthy range. It has decreased from 10.28 (Mar 23) to 9.85, marking a decrease of 0.43.
For Diluted EPS (Rs.), as of Mar 24, the value is 9.85. This value is within the healthy range. It has decreased from 10.28 (Mar 23) to 9.85, marking a decrease of 0.43.
For Cash EPS (Rs.), as of Mar 24, the value is 10.37. This value is within the healthy range. It has decreased from 11.07 (Mar 23) to 10.37, marking a decrease of 0.70.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 52.55. It has increased from 30.73 (Mar 23) to 52.55, marking an increase of 21.82.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 52.55. It has increased from 30.73 (Mar 23) to 52.55, marking an increase of 21.82.
For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 101.16. It has decreased from 142.12 (Mar 23) to 101.16, marking a decrease of 40.96.
For PBDIT / Share (Rs.), as of Mar 24, the value is 14.16. This value is within the healthy range. It has decreased from 16.69 (Mar 23) to 14.16, marking a decrease of 2.53.
For PBIT / Share (Rs.), as of Mar 24, the value is 13.17. This value is within the healthy range. It has decreased from 15.59 (Mar 23) to 13.17, marking a decrease of 2.42.
For PBT / Share (Rs.), as of Mar 24, the value is 12.24. This value is within the healthy range. It has decreased from 13.10 (Mar 23) to 12.24, marking a decrease of 0.86.
For Net Profit / Share (Rs.), as of Mar 24, the value is 9.39. This value is within the healthy range. It has decreased from 9.96 (Mar 23) to 9.39, marking a decrease of 0.57.
For PBDIT Margin (%), as of Mar 24, the value is 13.99. This value is within the healthy range. It has increased from 11.74 (Mar 23) to 13.99, marking an increase of 2.25.
For PBIT Margin (%), as of Mar 24, the value is 13.02. This value is within the healthy range. It has increased from 10.96 (Mar 23) to 13.02, marking an increase of 2.06.
For PBT Margin (%), as of Mar 24, the value is 12.10. This value is within the healthy range. It has increased from 9.21 (Mar 23) to 12.10, marking an increase of 2.89.
For Net Profit Margin (%), as of Mar 24, the value is 9.27. This value is within the healthy range. It has increased from 7.00 (Mar 23) to 9.27, marking an increase of 2.27.
For Return on Networth / Equity (%), as of Mar 24, the value is 17.86. This value is within the healthy range. It has decreased from 32.42 (Mar 23) to 17.86, marking a decrease of 14.56.
For Return on Capital Employeed (%), as of Mar 24, the value is 23.37. This value is within the healthy range. It has decreased from 44.37 (Mar 23) to 23.37, marking a decrease of 21.00.
For Return On Assets (%), as of Mar 24, the value is 10.14. This value is within the healthy range. It has decreased from 11.78 (Mar 23) to 10.14, marking a decrease of 1.64.
For Long Term Debt / Equity (X), as of Mar 24, the value is 0.06. This value is below the healthy minimum of 0.2. It has decreased from 0.12 (Mar 23) to 0.06, marking a decrease of 0.06.
For Total Debt / Equity (X), as of Mar 24, the value is 0.12. This value is within the healthy range. It has decreased from 0.30 (Mar 23) to 0.12, marking a decrease of 0.18.
For Asset Turnover Ratio (%), as of Mar 24, the value is 1.31. It has decreased from 1.83 (Mar 23) to 1.31, marking a decrease of 0.52.
For Current Ratio (X), as of Mar 24, the value is 1.83. This value is within the healthy range. It has increased from 1.23 (Mar 23) to 1.83, marking an increase of 0.60.
For Quick Ratio (X), as of Mar 24, the value is 1.28. This value is within the healthy range. It has increased from 0.84 (Mar 23) to 1.28, marking an increase of 0.44.
For Inventory Turnover Ratio (X), as of Mar 24, the value is 4.47. This value is within the healthy range. It has decreased from 5.93 (Mar 23) to 4.47, marking a decrease of 1.46.
For Interest Coverage Ratio (X), as of Mar 24, the value is 15.21. This value is within the healthy range. It has increased from 6.70 (Mar 23) to 15.21, marking an increase of 8.51.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 11.09. This value is within the healthy range. It has increased from 5.00 (Mar 23) to 11.09, marking an increase of 6.09.
For Enterprise Value (Cr.), as of Mar 24, the value is 132.59. It has increased from 0.00 (Mar 23) to 132.59, marking an increase of 132.59.
For EV / Net Operating Revenue (X), as of Mar 24, the value is 1.26. This value is within the healthy range. It has increased from 0.00 (Mar 23) to 1.26, marking an increase of 1.26.
For EV / EBITDA (X), as of Mar 24, the value is 8.97. This value is within the healthy range. It has increased from 0.00 (Mar 23) to 8.97, marking an increase of 8.97.
For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 1.32. This value is within the healthy range. It has increased from 0.00 (Mar 23) to 1.32, marking an increase of 1.32.
For Price / BV (X), as of Mar 24, the value is 2.53. This value is within the healthy range. It has increased from 0.00 (Mar 23) to 2.53, marking an increase of 2.53.
For Price / Net Operating Revenue (X), as of Mar 24, the value is 1.32. This value is within the healthy range. It has increased from 0.00 (Mar 23) to 1.32, marking an increase of 1.32.
For EarningsYield, as of Mar 24, the value is 0.07. This value is below the healthy minimum of 5. It has increased from 0.00 (Mar 23) to 0.07, marking an increase of 0.07.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Hemant Surgical Industries Ltd as of April 25, 2025 is: 138.38

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of April 25, 2025, Hemant Surgical Industries Ltd is Undervalued by 30.55% compared to the current share price 106.00

Intrinsic Value of Hemant Surgical Industries Ltd as of April 25, 2025 is: 90.28

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of April 25, 2025, Hemant Surgical Industries Ltd is Overvalued by 14.83% compared to the current share price 106.00

Last 5 Year EPS CAGR: -34.76%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
The stock has a high average ROCE of 21.14%, which is a positive sign. The stock has a low average Working Capital Days of 29.57, which is a positive sign. The company has higher reserves (17.88 cr) compared to borrowings (10.75 cr), indicating strong financial stability. The company has shown consistent growth in sales (80.75 cr) and profit (5.75 cr) over the years.	The stock has a high average Cash Conversion Cycle of 24.43, which may not be favorable.

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Hemant Surgical Industries Ltd:
1. Net Profit Margin: 9.27%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: 23.37% (Industry Average ROCE: 29.8%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: 17.86% (Industry Average ROE: 25%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): 11.09
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 1.28
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 12.2 (Industry average Stock P/E: 12.2)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0.12
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

Hemant Surgical Industries Ltd. is a Public Limited Listed company incorporated on 27/03/1989 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L33110MH1989PLC051133 and registration number is 051133. Currently Company is involved in the business activities of Other Hospital and Medical Care Activities. Company's Total Operating Revenue is Rs. 105.61 Cr. and Equity Capital is Rs. 10.44 Cr. for the Year ended 31/03/2024.

INDUSTRY	ADDRESS	CONTACT
Medical Equipment & Accessories	502, 5th Floor, Ecstasy Business Park Co-Op Socteiy Limited, Mumbai Maharashtra 400080	info@hemantsurgical.com http://www.hemantsurgical.com

Management
Name	Position Held
Mr. Hanskumar Shamji Shah	Chairman & Managing Director
Mr. Kaushik Hanskumar Shah	WholeTime Director & CFO
Mr. Hemant Praful Shah	Whole Time Director
Mrs. Nehal Babu Karelia	Non Executive Director
Mrs. Pooja Kirti Kothari	Independent Director
Mr. Sourabh Ajmera	Independent Director

FAQ

What is the intrinsic value of Hemant Surgical Industries Ltd?

Hemant Surgical Industries Ltd's intrinsic value (as of 25 April 2025) is ₹138.38 — 30.55% higher the current market price of 106.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 111 Cr. market cap, FY2025-2026 high/low of ₹225/88.2, reserves of 48 Cr, and liabilities of 116 Cr.

What is the Market Cap of Hemant Surgical Industries Ltd?

The Market Cap of Hemant Surgical Industries Ltd is 111 Cr..

What is the current Stock Price of Hemant Surgical Industries Ltd as on 25 April 2025?

The current stock price of Hemant Surgical Industries Ltd as on 25 April 2025 is 106.

What is the High / Low of Hemant Surgical Industries Ltd stocks in FY 2025-2026?

In FY 2025-2026, the High / Low of Hemant Surgical Industries Ltd stocks is ₹225/88.2.

What is the Stock P/E of Hemant Surgical Industries Ltd?

The Stock P/E of Hemant Surgical Industries Ltd is 12.2.

What is the Book Value of Hemant Surgical Industries Ltd?

The Book Value of Hemant Surgical Industries Ltd is 55.6.

What is the Dividend Yield of Hemant Surgical Industries Ltd?

The Dividend Yield of Hemant Surgical Industries Ltd is 0.00 %.

What is the ROCE of Hemant Surgical Industries Ltd?

The ROCE of Hemant Surgical Industries Ltd is 29.8 %.

What is the ROE of Hemant Surgical Industries Ltd?

The ROE of Hemant Surgical Industries Ltd is 25.0 %.

What is the Face Value of Hemant Surgical Industries Ltd?

The Face Value of Hemant Surgical Industries Ltd is 10.0.